Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02484456|
Recruitment Status : Recruiting
First Posted : June 29, 2015
Last Update Posted : October 19, 2018
- Drugs and talk therapy help treat depression, but these treatments usually take quite a bit of time to work. Ketamine is a fast-acting antidepressant, but it has side effects like unusual dreams and experiences. The drug AV-101 may have the same antidepressant effects but fewer side effects. Researchers want to see if it is effective and safe for people with major depressive disorder.
- To see if the drug, AV-101 is safe and if it treats symptoms of major depressive disorder.
- Adults ages 18-65 with major depression without psychotic features.
- Participants will be screened under a separate protocol.
- Participants will stay in the hospital for 12-14 weeks.
- Phase 1 (2-7 weeks): participants will stop taking their medicines then not take any for 2 weeks. They will have several scans and other procedures.
- Phase 2 (6-7 weeks): 2 weeks each of study drug and placebo once a day, with 2 weeks of no drugs in between.
- Participants will have:
- Physical exams
- Frequent blood collection. A needle will place a small plastic tube in the arm. Some blood samples will be taken through this tube.
- 2 spinal taps (optional). The back will be numbed. A needle will insert a catheter between back bones. That will be left in for up to 30 hours. Spinal fluid will be collected through it.
- 5 scans. Participants will lie in a machine with a magnetic field. The machine takes pictures of the brain and brain chemicals.
- At the end of the study, participants will have medical evaluation, questions, and blood tests. Some may continue treatment at the clinic.
|Condition or disease||Intervention/treatment||Phase|
|Major Depression||Drug: AV 101 (4-Chlorokynurenine) Other: Placebo||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||25 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||An Investigation of the Antidepressant Effects of the Glycine Receptor Antagonist AV 101 (4-chlorokynurenine) in Major Depressive Disorder|
|Study Start Date :||June 19, 2015|
|Estimated Primary Completion Date :||December 31, 2019|
|Estimated Study Completion Date :||December 31, 2019|
Placebo Comparator: Test Session 2
2 weeks of single daily dose of placebo pill
Experimental: Test Session 1
2 weeks of 1,080 or 1,440 mg/day (single daily dose) of study drug
Drug: AV 101 (4-Chlorokynurenine)
Glycine Receptor Antagonist
- Change from baseline in the Hamilton Depression Rating scale total score. [ Time Frame: Multiple timepoints ]
- Change from baseline in BPRS, CADSS, C-SSRS, HAM-A, HDRS, MADRS, PANAS, SHAPS, SSI, TEPS, YMRS total scores. [ Time Frame: Multiple ]
- Change from baseline in the C-SSRS total score. [ Time Frame: Multiple ]
- Proportion of subjects with response (defined as greater than or equal to 50% reduction from baseline in HDRS total score [ Time Frame: Multiple ]
- Proportion of subjects in remission (defined as HDRS total score less than or equal to 7 [ Time Frame: End of test sessions ]
- Incidence and nature of adverse events; vital signs; weight and body mass index (BMI) changes; physical examination changes; clinical laboratory evaluations; ECG. [ Time Frame: Multiple ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02484456
|Contact: Libby Jolkovsky||(877) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||Carlos A Zarate, M.D.||National Institute of Mental Health (NIMH)|